OIM
SLNO

Oracle Investment Management’s Soleno Therapeutics SLNO Stock Holding History

Oracle Investment Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-142,133
Closed -$394K – 28
2022
Q2 		$394K Hold
142,133
– – 0.12% 24
2022
Q1 		$475K Hold
142,133
– – 0.09% 27
2021
Q4 		$874K Hold
142,133
– – 0.12% 23
2021
Q3 		$1.97M Hold
142,133
– – 0.25% 24
2021
Q2 		$2.43M Hold
142,133
– – 0.33% 24
2021
Q1 		$2.69M Sell
142,133
-102,559
-42% -$3.31M 0.4% 20
2020
Q4 		$7.08M Hold
244,692
– – 0.89% 11
2020
Q3 		$9.21M Hold
244,692
– – 1.21% 8
2020
Q2 		$8.15M Sell
244,692
-13,350
-5% -$579K 1.03% 10
2020
Q1 		$9.21M Hold
258,042
– – 2.74% 5
2019
Q4 		$11.4M Hold
258,042
– – 2.14% 6
2019
Q3 		$5.81M Buy
258,042
+3,805
+1% +$121K 1.43% 8
2019
Q2 		$10.7M Hold
254,237
– – 2.3% 7
2019
Q1 		$7.86M Buy
254,237
+8,691
+4% +$231K 1.67% 11
2018
Q4 		$6.3M Buy
245,546
+83,009
+51% +$2.42M 1.95% 10
2018
Q3 		$5.27M Hold
162,537
– – 1.15% 11
2018
Q2 		$5.71M Buy
162,537
+3,333
+2% +$97.7K 1.38% 11
2018
Q1 		$4.33M Hold
159,204
– – 1.05% 15
2017
Q4 		$4.3M Buy
+159,204
New +$4.59M 0.85% 14

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
CP
Clayton Partners Berkeley, California $138M AUM 38.58% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oracle Investment Management's SLNO Position: Q3 2022 in Review

Oracle Investment Management sold out of Soleno Therapeutics (SLNO) in Q3 2022, closing a stake of 142,133 shares — an estimated $394K sold.

Oracle Investment Management first reported a position in SLNO in Q4 2017 and held it in 19 quarters. The position peaked at $11.4M in Q4 2019. 22 funds tracked by Wall St. Rank hold SLNO as of Q3 2022.

  • Oracle Investment Management reported no remaining Soleno Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Oracle Investment Management sold 142,133 Soleno Therapeutics shares in Q3 2022, an estimated $394K.
  • Oracle Investment Management first reported a position in Soleno Therapeutics in Q4 2017 and held it in 19 quarters.
  • Oracle Investment Management's Soleno Therapeutics position peaked at $11.4M in Q4 2019.
  • 22 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2022.

Based on Oracle Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.